Lexaria Bioscience Corp.

Lexaria Bioscience Corp. (ticker: LEXX) is an NASDAQ-listed pharmaceutical preparations company. DredgeCap's structured extraction of LEXX's SEC filings surfaces 3 active risk signals, including 1 auditor-change signal, 1 delisting/deregistration signal, and 1 late-filing signal. LEXX reported $20K in revenue and -$3.04M for the period ending 2026-02-28, with operating cash flow of -$3.15M. Cash and equivalents stood at $5.10M (down 21.5% year-over-year). Total assets of $6.49M exceed total liabilities of $277K. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.